- 全部删除
您的购物车当前为空
Fenebrutinib is orally available inhibitor of Bruton's tyrosine kinase (BTK) with antineoplastic activity. Upon administration, GDC-0853 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, leading to the inhibition of the growth of malignant B-cells that overexpress BTK.

Fenebrutinib is orally available inhibitor of Bruton's tyrosine kinase (BTK) with antineoplastic activity. Upon administration, GDC-0853 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, leading to the inhibition of the growth of malignant B-cells that overexpress BTK.
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 25 mg | ¥ 10,600 | 1-2周 |
| 产品描述 | Fenebrutinib is orally available inhibitor of Bruton's tyrosine kinase (BTK) with antineoplastic activity. Upon administration, GDC-0853 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, leading to the inhibition of the growth of malignant B-cells that overexpress BTK. |
| 别名 | RG-7845, RG7845, RG 7845, GDC-0853, GDC0853, GDC 0853 |
| 分子量 | 701.27 |
| 分子式 | C37H45ClN8O4 |
| CAS No. | 2128304-54-9 |
| 密度 | 1.31g/cm3 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容